Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2024-203704

Published: 2024

Journal Articles

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Uma Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel J. Cook, Jennifer N. Saultz, Ronan T. Swords, Nicole R. Grieselhuber, Alice Mims, Karilyn T. Larkin, Kieran D Sahasrabudhe, James S. Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig

Blood (2024) 144 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2024-210605

Published: 2024

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 7309.

https://doi.org/10.1182/blood-2024-202650

Published: 2024

Journal Articles

A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR :: ABL -Positive Leukemias

Amog Urs, Dimitrios Papaioannou, Rohan Kulkarni, Chinmayee Goda, Remi Buisson, Deedra Nicolet, Lauren Woodward, Krzysztof Mrózek, Gregory K Behbehani, Sakari Kauppinen, Ann-Kathrin Eisfeld, Iannis Aifantis, Guramrit Singh, Adrienne M. Dorrance, Ramiro Garzon

Blood (2024) 144 (Supplement 1): 954.

https://doi.org/10.1182/blood-2024-208650

Published: 2024

Journal Articles

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Blood (2024) 144 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2024-207532

Published: 2024

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

CD38 KO /CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma

Ella C Troy, Yasemin Sezgin, Marcelo De Souza Pereira, Joseph Caporale, Gregory K Behbehani, Justin Lyberger, Dean Anthony Lee, Meisam Naeimi Kararoudi

Blood (2023) 142 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2023-174742

Published: 2023

Journal Articles

CircPCMTD1 : A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts

Dimitrios Papaioannou, MD, Remi Buisson, Andreas Petri, PhD, Allison Walker, Marius Bill, MD PhD, Felice Pepe, PhD, Deedra Nicolet, MS, Lauren A Woodward, Krzysztof Mrózek, MD PhD, Malith Karunasiri, Gregory K. Behbehani, MD PhD, Emanuele Cocucci, PhD, Guramrit Singh, PhD, Sakari Kauppinen, PhD, Adrienne M. Dorrance, PhD, Clara D. Bloomfield, MD, Ramiro Garzon, MD

Blood (2019) 134 (Supplement_1): 640.

https://doi.org/10.1182/blood-2019-126223

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Caner Saygin, MD, Arletta Lozanski, Tzyy-Jye Doong, Shelley Orwick, BS, Deedra Nicolet, MS, Jadwiga Labanowska, Nyla A. Heerema, PhD, Rosa Lapalombella, PhD, Gregory K. Behbehani, MD PhD, John C. Byrd, MD, Gerard Lozanski, MD, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 186.

https://doi.org/10.1182/blood-2019-125285

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Bhavana Bhatnagar, DO, Rebecca B. Klisovic, MD, Alison R. Walker, MD MPH, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Katherine J. Walsh, MD, Gregory K. Behbehani, MD PhD, James S. Blachly, MD, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, MAS, Shelley Orwick, BS, Parvathi Ranganathan, PhD, John C. Byrd, MD, William Blum, MD, Ramiro Garzon, MD

Blood (2016) 128 (22): 1651.

https://doi.org/10.1182/blood.V128.22.1651.1651

Published: 2016

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML)

Changxian Shen, Dimitrios Papaioannou, MD, Betina Mcneil, Deedra Nicolet, Malith Karunasiri, Matthew Burke, Zitzer Nina, Gregory K. Behbehani, MD PhD, Hatice G Ozer, PhD, Selen Yilmaz, Guido Marcucci, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Ramiro Garzon, MD, Adrienne Dorrance, PhD

Blood (2016) 128 (22): 2689.

https://doi.org/10.1182/blood.V128.22.2689.2689

Published: 2016

Journal Articles

Profiling Myelodysplastic Syndromes By Mass Cytometry Demonstrates Distinct Immunophenotypic Aberrancies in Stem and Progenitor Populations

Gregory K. Behbehani, MD PhD, Rachel Finck, B.S., Nikolay Samusik, PhD, Pier Federico Gherardini, PhD, Kunju J Sridhar, PhD, Wendy J. Fantl, PhD, Peter L. Greenberg, MD, Garry P. Nolan, PhD

Blood (2014) 124 (21): 1903.

https://doi.org/10.1182/blood.V124.21.1903.1903

Published: 2014

Journal Articles

Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Cell Cycle Properties That Correlate with Known Responses to Chemotherapy

Gregory K. Behbehani, MD PhD, Wendy J. Fantl, PhD, Bruno C Medeiros, MD, Garry P. Nolan, PhD

Blood (2014) 124 (21): 2359.

https://doi.org/10.1182/blood.V124.21.2359.2359

Published: 2014

Journal Articles

Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Immunophenotypes That May Represent Targets for Antibody-Directed Therapies

Gregory K. Behbehani, MD PhD, Wendy J. Fantl, PhD, Bruno C Medeiros, MD, Garry P. Nolan, PhD

Blood (2014) 124 (21): 2380.

https://doi.org/10.1182/blood.V124.21.2380.2380

Published: 2014

Journal Articles

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Daniel A.C. Fisher, PhD, Olga Malkova, Mary C. Fulbright, Gregory K. Behbehani, MD PhD, Garry P. Nolan, PhD, Stephen T. Oh, MD PhD

Blood (2014) 124 (21): 1884.

https://doi.org/10.1182/blood.V124.21.1884.1884

Published: 2014

NARROW

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR :: ABL -Positive Leukemias

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

CD38 KO /CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma

CircPCMTD1 : A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML)

Profiling Myelodysplastic Syndromes By Mass Cytometry Demonstrates Distinct Immunophenotypic Aberrancies in Stem and Progenitor Populations

Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Cell Cycle Properties That Correlate with Known Responses to Chemotherapy

Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Immunophenotypes That May Represent Targets for Antibody-Directed Therapies

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only